explore -WSS

explore

author：leisure time 2025-10-03 00:22:25 - browse：79

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Shionogi licenses Pompe disease therapy from Maze Therapeutics

WSS

Dairy farmers resist CDC push for PPE against bird flu virus

FDA approves Moderna’s RSV vaccine, its second licensed product

An outdated Medicare rule harms dementia patients with anxiety

H5N1 communication has been strictly for the birds

Telehealth startups turn to complex chronic diseases

Eli Lilly’s Zepbound improved liver scarring in mid

hotspot

explore

focus

Hepatitis C has a cure — but many Americans still lack access to it

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Cancer drug shortages should be causing more outrage

Take antibiotics after sex, CDC recommends for certain risk groups

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Researchers on aging grapple with how to calculate biological age

Psychedelics group wrestles with new pharma identity

Stopping antidepressants leads to symptoms for 1 in 6 patients

Hollywood unions extend contract negotiations for actors

FTC loses bid to block Novant's North Carolina hospital merger

focus

Stopping antidepressants leads to symptoms for 1 in 6 patients

Eli Lilly’s Zepbound improved liver scarring in mid

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Google says AlphaFold 3 can map a vast universe of biomolecules

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Stopping antidepressants leads to symptoms for 1 in 6 patients

leisure time

focus

hotspot

Wikipedia